BVS NASDAQ
Bioventus Inc.
1W: -10.6%
1M: -2.9%
3M: +10.6%
YTD: +31.6%
1Y: +35.8%
3Y: +690.8%
5Y: -40.1%
$9.28
-0.21 (-2.26%)
Weekly Expected Move ±6.1%
$9
$10
$11
$11
$12
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
0.00
Neutral
0 bullish
0 neutral
0 bearish
Articles (24h)
0
No articles in the last 24 hours
0.00
Neutral
1 bullish
0 neutral
1 bearish
Articles (7d)
2
Daily Sentiment (7 Days)
Articles (39)
Is Bioventus (BVS) Stock Undervalued Right Now?
Are Medical Stocks Lagging Bioventus (BVS) This Year?
Wall Street Analysts See a 38.97% Upside in Bioventus (BVS): Can the Stock Really Move This High?
Earnings Scheduled For May 6, 2026
Bioventus Inc. Q1 2026 Earnings Call Summary
Bioventus (BVS) Q1 2026 Earnings Transcript
Bioventus outlines 2026 adjusted EPS of $0.75-$0.79 while reaffirming $600M-$610M revenue
Bioventus (BVS) Surpasses Q1 Earnings and Revenue Estimates
[10-Q] Bioventus Inc. Quarterly Earnings Report - Stock Titan
Bioventus Non-GAAP EPS of $0.15 beats by $0.08, revenue of $132.1M beats by $2.2M
Bioventus Reports First Quarter Financial Results
Bioventus Reports First Quarter Financial Results
Should Value Investors Buy Bioventus (BVS) Stock?
Are Medical Stocks Lagging ADC Therapeutics (ADCT) This Year?
TELA Bio Announces Strategic Board Refreshment with Four Highly Experienced Commerical Leaders to Accelerate Growth and Drive Path to Profitability; The Company Also Reports Preliminary First Quarter 2026 Revenues
Are Investors Undervaluing Amneal Pharmaceuticals (AMRX) Right Now?
Bioventus to Report First Quarter of Fiscal Year 2026 Financial Results on May 6, 2026
Strength Seen in Bioventus (BVS): Can Its 6.6% Jump Turn into More Strength?
12 Health Care Stocks Moving In Tuesday's After-Market Session
Are Investors Undervaluing Bioventus (BVS) Right Now?
Bioventus Inc. (NASDAQ:BVS) Given Consensus Rating of “Buy” by Brokerages
Bioventus Inc. (NASDAQ:BVS) Receives $14.25 Consensus PT from Analysts
Bioventus (NASDAQ:BVS) Shares Gap Up After Analyst Upgrade
Bioventus outlines $600M–$610M 2026 sales target with accelerated investment in PNS, PRP, and ultrasonics
Bioventus (BVS) Q4 2025 Earnings Call Transcript
Bioventus Q4 Earnings Assessment
Bioventus Non-GAAP EPS of $0.24 beats by $0.02, revenue of $157.9M beats by $2.95M
Bioventus Earnings Report: Q4 Overview
Bioventus Announces Fourth Quarter and Full Year 2025 Financial Results
Earnings Scheduled For March 5, 2026
Preview: Bioventus's Earnings
Bioventus (NYSE:BVS) Stock Price Down 0.1% – Should You Sell?
Bioventus to Report Fourth Quarter of Fiscal Year 2025 Financial Results on March 5, 2026
Bioventus Inc. (BVS) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Bioventus to Present at the 44th Annual J.P. Morgan Healthcare Conference
Medifocus (OTCMKTS:MDFZF) versus Bioventus (NYSE:BVS) Head-To-Head Comparison
Bioventus (NYSE:BVS) Trading Down 1.1% – Time to Sell?
HALPER SADEH LLC ENCOURAGES BIOVENTUS INC. SHAREHOLDERS TO CONTACT THE FIRM TO DISCUSS THEIR RIGHTS
Bioventus to Present at the Piper Sandler 37th Annual Healthcare Conference